It was a great pleasure to meet with Anthony Tang to discuss the RAFT-AF trial results investigating the safety and efficacy of catheter ablation-based rhythm control compared with rate control for the treatment of patients with atrial fibrillation and heart failure, presented at ACC 2021.
- What were the aims and design of the RAFT study? (0:19)
- What were the key inclusion criteria of the study? (0:44)
- Could you tell us a little about the study findings in terms of primary and secondary outcomes, and the reasons for early termination of the study? (1:44)
- How did these findings compare with other studies comparing rhythm-control and rate-control strategies among patients with atrial fibrillation and heart failure? (5:58)
- What are the implications of these findings for the management of patients with atrial fibrillation and heart failure, and what future studies are needed? (7:50)
Speaker disclosures: Anthony Tang has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed during a remote video call with Professor Anthony Tang as a highlight of ACC 2021, May 2021.
Share this Video
Related Videos In Heart Failure
Anthony Tang, ACC 2021: Findings from the RAFT-AF Trial
It was a great pleasure to meet with Anthony Tang to discuss the RAFT-AF trial results investigating the safety and efficacy of catheter ablation-based rhythm control compared with rate control for the treatment of patients with atrial fibrillation and heart failure, presented at ACC 2021. Abstract Title: A Randomized Ablation-based atrial Fibrillation rhythm control versus […]
Michiel Rienstra and Bao-Oanh Nguyen, EHRA 2021 – Long-term Outcomes of the RACE 3 Trial
Professor Michiel Rienstra and Dr Bao-Oanh Nguyen (University Medical Center Groningen, Groningen, The Netherlands) gave us an overview of the RACE-3 study (NCT00877643) from the European Heart Rhythm Association (EHRA) Virtual Meeting 2021. Questions: What is the rationale for targeted therapy of underlying conditions in patients with persistent atrial fibrillation (AF) and mild to moderate […]
Hugh Calkins, AF Symposium 2021: Atrial Fibrillation and HFrEF and HFpEF
We spoke to Professor Hugh Calkins (Johns Hopkins Hospital, Baltimore, MD, USA) about atrial fibrillation and heart failure with reduced and preserved ejection fraction. Questions: What is the prevalence of atrial fibrillation (AF) in patients with heart failure (HF) and reduced (HFrEF) and preserved (HFpEF) ejection fraction? (0.13) What is the impact of AF on […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!